longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

BioNexus Gene Lab

BGLC

1.4702.00% ( -0.030 )
Trading: Sep 15, 09:47:42 (EDT)
Start trading
OverviewOverviewOptionsOptionsNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is -1.71, above the reasonable range, cheaper than 9.21% of the time in the past 3 years, and the industry ranks 42/56, the industry Median 18.03.

-1.71xP/E
$1.50Stock price
$-0.88Earnings per share
-1.71xP/E
Stock price$1.50Earnings per share$-0.88

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
-3.26x
Typical range
-4.42x–-2.34x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
Industry median 18.03x
06121824

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
Industry median 18.03x
0x30x60x90x120x150x
P/E ratio
Name/Symbol
QXOUSQXO
-19.14x12.70%$12.56B
XMTRUSXometry
-158.20x85.53%$4.87B
DNOWUSDNOW
-15.04x80.70%$2.83B
BXCUSBluelinx
-318.08x4,600.00%$619.62M
TITNUSTitan Machinery
-10.06x32.77%$570.67M
ZKHUSZKH
-1,122.56x164.00%$472.23M
ALTGUSAlta Equipment
-2.34x48.82%$194.69M
NPTUSTexxon
-22.26x--$62.34M
SPPLUSSimpple
-6.53x--$21.09M
MWYNUSMarwynn
-5.15x--$20.19M
FGIUSFGI Industries
-4.37x77.50%$17.28M
OPTIUSOptec International, Inc.
----$8.07M
MWGUSMulti Ways
-15.68x--$6.79M
BGLCUSBioNexus Gene Lab
-1.71x--$4.40M
CAPSUSCapstone
-0.16x104.85%$3.50M
IPWUSiPower
-0.23x--$1.85M
LVROFUSLAVORO LIMITED
-0.00x--$114.97K
MKDTYUSMolecular Data Inc.
----$1.22K

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.